Scapular Muscle Activation and Shoulder Performance in Migraine
15. juni 2026 oppdatert av: Ankara Yildirim Beyazıt University
INVESTIGATION OF SCAPULAR MUSCLE ACTIVATION AND SHOULDER PERFORMANCE IN INDIVIDUALS WITH MIGRAINE
Migraine is a significant health problem due to its high prevalence and substantial contribution to disability.
Individuals with migraine have been reported to exhibit myofascial trigger points, increased pain sensitivity, and altered muscle activation patterns, particularly in the trapezius muscles.
As the upper and middle trapezius muscles play critical roles in scapular stability and movement, alterations in these muscles may affect scapular orientation and upper extremity function.
However, studies investigating the relationship between trapezius muscle activation, scapular orientation, and upper extremity performance in individuals with migraine are limited.
Therefore, this study aimed to compare trapezius muscle activation, scapular orientation, and upper extremity performance between individuals with and without migraine.
We hypothesized that individuals with migraine would exhibit altered upper and middle trapezius muscle activation, impaired scapular orientation, and reduced upper extremity performance compared with healthy controls.
Studieoversikt
Status
Rekruttering
Forhold
Studietype
Observasjonsmessig
Registrering (Antatt)
50
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Çubuk
-
Ankara, Çubuk, Tyrkia (Türkiye), 06760
- Rekruttering
- Ankara Yıldırım Beyazıt University
-
Ta kontakt med:
- Yasemin Ankara Yıldırım Beyazıt University
- Telefonnummer: 05397799535
- E-post: yaseminates48@gmail.com
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Prøvetakingsmetode
Sannsynlighetsprøve
Studiepopulasjon
Adults diagnosed with migraine according to the ICHD-3 criteria
Beskrivelse
Inclusion Criteria:
- Aged 18-55 years
- Diagnosed with migraine by a neurologist according to the ICHD-3 criteria
- Experiencing at least 3 migraine attacks per month
- Willing to participate and provide written informed consent
Exclusion Criteria:
- Presence of other types of headache disorders
- History of trauma, fracture, or surgery involving the cranio-cervical region, scapular region, or upper extremity
- Presence of neurological or inflammatory rheumatic diseases
- Presence of psychiatric disorders
- Receiving physiotherapy or rehabilitation for migraine or the cervical, thoracic, or upper extremity regions within the past 6 months
- Cognitive impairment affecting the understanding of test instructions
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Styre
|
|
Migrene
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Trapezius muscle activity
Tidsramme: Single assessment at baseline
|
Upper and middle trapezius muscle activations will be assessed on the dominant side using surface electromyography (sEMG).
Following skin preparation, EMG sensors will be placed over the upper and middle trapezius muscles according to the recommendations of the Surface Electromyography for the Non-Invasive Assessment of Muscles (SENIAM).
Resting muscle activity will be recorded prior to measurements to ensure signal quality.
Muscle activations will first be recorded during maximal voluntary isometric contraction (MVIC) and subsequently during arm elevation in the scapular plane.
EMG data will be analyzed using EMGworks software; signals will be filtered, processed using the root mean square (RMS) method, and normalized to each participant's MVIC values, expressed as %MVIC.
Additionally, upper trapezius/middle trapezius activation ratios will be calculated, and muscle activation levels will be categorized according to predefined threshold values.
|
Single assessment at baseline
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Scapular rotation
Tidsramme: Single assessment at baseline
|
Scapular upward rotation will be assessed using a digital inclinometer at shoulder elevation angles of 0°, 45°, 90°, and 135°.
Participants will stand comfortably with the elbow extended and elevate the arm with the thumb pointing upward to the target angles.
The inclinometer will be positioned over the scapular spine to measure scapular upward rotation at each angle.
Three measurements will be obtained at each position with 30-second rest intervals, and the mean value will be used for analysis.
|
Single assessment at baseline
|
|
Pain
Tidsramme: Single assessment at baseline
|
The pressure pain threshold of the upper trapezius muscle will be assessed using a digital algometer.
Measurements will be performed at the midpoint between the C7 vertebra and the acromion using a 1-cm diameter rubber probe.
Pressure will be gradually increased until the participant first reports pain or discomfort.
Three measurements will be obtained with 30-second intervals, and the mean value (N/m²) will be used for analysis.
|
Single assessment at baseline
|
|
Upper extremity performance
Tidsramme: Single assessment at baseline
|
Upper extremity mobility, stability, and proprioception in a closed kinetic chain will be assessed using the Upper Quarter Y-Balance Test.
Participants will perform the test in a push-up position while reaching in the medial, inferolateral, and superolateral directions with the free hand.
Reach distances will be recorded in centimeters and normalized to upper extremity length.
Composite reach scores will also be calculated, with greater reach distances indicating better upper extremity dynamic balance and function.
|
Single assessment at baseline
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. april 2026
Primær fullføring (Antatt)
1. juli 2026
Studiet fullført (Antatt)
15. juli 2026
Datoer for studieregistrering
Først innsendt
15. juni 2026
Først innsendt som oppfylte QC-kriteriene
15. juni 2026
Først lagt ut (Faktiske)
18. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
18. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
15. juni 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2026076
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .